GLP-1 receptor agonists, such as Semaglutide and Tirzepatide, are designed to mimic a hormone your body naturally produces
Using hierarchical clustering, 30 clusters of biomarkers were created based on participants biomarker profiles
Risk of an infeasible or underpowered trial Given the aforementioned logistical, ethical and financial issues, a 2-arm RCT comparing the use of GLP-1 drugs for cancer prevention may not be feasible in the real world
*STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss Versus Semaglutide 2.4 mg and Placebo.* January 2025
At least three self-insured customers of Blue Cross employers that pay their own insurance claims and thus arent subject to the terms of Blue Cross benefits already have declined to cover the drugs for weight loss, McHugh said
Nature Reviews Disease Primers Boachie J, Adaikalakoteswari A, Samavat J, Saravanan P